Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations

v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 6,971,005 $ 5,464,250
General and administrative 1,673,890 1,995,845
Total operating expenses 8,644,895 7,460,095
Loss from operations (8,644,895) (7,460,095)
Other income 400,523 112,192
Net loss $ (8,244,372) $ (7,347,903)
Net loss per share, basic (in dollars per share) $ (1.26) $ (5.27)
Net loss per share, diluted (in dollars per share) $ (1.26) $ (5.27)
Weighted-average outstanding Common Shares, basic (in shares) 6,527,779 1,394,048
Weighted-average outstanding Common Shares, diluted (in shares) 6,527,779 1,394,048